138 related articles for article (PubMed ID: 29651478)
1. Halogen-like properties of the Al
Molina B; Soto JR; Castro JJ
Phys Chem Chem Phys; 2018 May; 20(17):11549-11553. PubMed ID: 29651478
[TBL] [Abstract][Full Text] [Related]
2. Unexpected Behavior of the Heaviest Halogen Astatine in the Nucleophilic Substitution of Aryliodonium Salts.
Guérard F; Lee YS; Baidoo K; Gestin JF; Brechbiel MW
Chemistry; 2016 Aug; 22(35):12332-9. PubMed ID: 27305065
[TBL] [Abstract][Full Text] [Related]
3. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles.
Pozzi OR; Zalutsky MR
J Nucl Med; 2005 Apr; 46(4):700-6. PubMed ID: 15809494
[TBL] [Abstract][Full Text] [Related]
4. Bifunctional aryliodonium salts for highly efficient radioiodination and astatination of antibodies.
Guérard F; Navarro L; Lee YS; Roumesy A; Alliot C; Chérel M; Brechbiel MW; Gestin JF
Bioorg Med Chem; 2017 Nov; 25(21):5975-5980. PubMed ID: 28964629
[TBL] [Abstract][Full Text] [Related]
5. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.
Zalutsky MR; Vaidyanathan G
Curr Pharm Des; 2000 Sep; 6(14):1433-55. PubMed ID: 10903402
[TBL] [Abstract][Full Text] [Related]
6. Advances in the Chemistry of Astatine and Implications for the Development of Radiopharmaceuticals.
Guérard F; Maingueneau C; Liu L; Eychenne R; Gestin JF; Montavon G; Galland N
Acc Chem Res; 2021 Aug; ():. PubMed ID: 34350753
[TBL] [Abstract][Full Text] [Related]
7. Construction and Preclinical Evaluation of 211At Labeled Anti-mesothelin Antibodies as Potential Targeted Alpha Therapy Drugs.
Wang X; Ma W; Liu W; Ma H; Yang Y; Wang Y; Liu N; Yang G
J Radiat Res; 2020 Sep; 61(5):684-690. PubMed ID: 32648573
[TBL] [Abstract][Full Text] [Related]
8. Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials.
Aneheim E; Albertsson P; Bäck T; Jensen H; Palm S; Lindegren S
Sci Rep; 2015 Jul; 5():12025. PubMed ID: 26169786
[TBL] [Abstract][Full Text] [Related]
9. Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals.
Pruszyński M; Łyczko M; Bilewicz A; Zalutsky MR
Nucl Med Biol; 2015 May; 42(5):439-445. PubMed ID: 25687450
[TBL] [Abstract][Full Text] [Related]
10. Production of α-particle emitting ²¹¹At using 45 MeV α-beam.
Kim G; Chun K; Park SH; Kim B
Phys Med Biol; 2014 Jun; 59(11):2849-60. PubMed ID: 24819557
[TBL] [Abstract][Full Text] [Related]
11. Production, isolation, and shipment of clinically relevant quantities of astatine-211: A simple and efficient approach to increasing supply.
McIntosh LA; Burns JD; Tereshatov EE; Muzzioli R; Hagel K; Jinadu NA; McCann LA; Picayo GA; Pisaneschi F; Piwnica-Worms D; Schultz SJ; Tabacaru GC; Abbott A; Green B; Hankins T; Hannaman A; Harvey B; Lofton K; Rider R; Sorensen M; Tabacaru A; Tobin Z; Yennello SJ
Nucl Med Biol; 2023; 126-127():108387. PubMed ID: 37837782
[TBL] [Abstract][Full Text] [Related]
12. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for
Pozzi OR; Zalutsky MR
Nucl Med Biol; 2017 Mar; 46():43-49. PubMed ID: 28013121
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (alpha,2n)211 at reaction.
Larsen RH; Wieland BW; Zalutsky MR
Appl Radiat Isot; 1996 Feb; 47(2):135-43. PubMed ID: 8852627
[TBL] [Abstract][Full Text] [Related]
14. Organoastatine chemistry. Astatination via electrophilic destannylation.
Milius RA; McLaughlin WH; Lambrecht RM; Wolf AP; Carroll JJ; Adelstein SJ; Bloomer WD
Int J Rad Appl Instrum A; 1986; 37(8):799-802. PubMed ID: 3021681
[TBL] [Abstract][Full Text] [Related]
15. Shelf-life of ɛ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, precursors for 211At labeling of antibodies.
Aneheim E; Halleröd J; Albertsson P; Jensen H; Holgersson S; Lindegren S
Cancer Biother Radiopharm; 2015 Feb; 30(1):41-5. PubMed ID: 25588020
[TBL] [Abstract][Full Text] [Related]
16.
Maingueneau C; Berdal M; Eychenne R; Gaschet J; Chérel M; Gestin JF; Guérard F
Chemistry; 2022 Feb; 28(11):e202104169. PubMed ID: 34965315
[TBL] [Abstract][Full Text] [Related]
17. Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.
Eriksson SE; Elgström E; Bäck T; Ohlsson T; Jensen H; Nilsson R; Lindegren S; Tennvall J
Cancer Biother Radiopharm; 2014 Aug; 29(6):238-46. PubMed ID: 24971673
[TBL] [Abstract][Full Text] [Related]
18. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination.
Wilbur DS; Chyan MK; Hamlin DK; Vessella RL; Wedge TJ; Hawthorne MF
Bioconjug Chem; 2007; 18(4):1226-40. PubMed ID: 17583925
[TBL] [Abstract][Full Text] [Related]
19. Experimental and computational evidence of halogen bonds involving astatine.
Guo N; Maurice R; Teze D; Graton J; Champion J; Montavon G; Galland N
Nat Chem; 2018 Apr; 10(4):428-434. PubMed ID: 29556053
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates.
Aneheim E; Gustafsson A; Albertsson P; Bäck T; Jensen H; Palm S; Svedhem S; Lindegren S
Bioconjug Chem; 2016 Mar; 27(3):688-97. PubMed ID: 26791409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
